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Abstract
Fibromyalgia (FM) is a syndrome that presents primarily in women and is characterized 
by generalized pain, muscle rigidity, poor quality of sleep, fatigue, cognitive dysfunc-
tion, anxiety, episodes of depression, overall sensitivity, and deterioration in the perfor-
mance of day-to-day activities. In the pathophysiology of fibromyalgia neuroendocrine 
factors, anomalies of the autonomous nervous system, genetic characteristics, and envi-
ronmental and psychosocial factors are implicated. Alterations to the cells of the central 
nervous system that are present in fibromyalgia are due to the toxic effects of free radi-
cals by the high concentrations of polyunsaturated fatty acids of the membranes that are 
easily oxidized and the low level of protective antioxidant enzymes. In FM, defects are 
produced in any part of the cycle in the generation of adenosine-5′-triphosphate (ATP) 
by the mitochondria, which can alter energy production by the mitochondria and cause 
the characteristic symptoms of FM. The degradation of the mitochondria dependent 
on autophagy or mitophagy is an important process for maintaining the critical integ-
rity of the mitochondria and limiting the production of reactive oxygen species (ROS). 
Therefore, the deregulation of autophagy and mitochondrial dysfunction could repre-
sent key aspects in the pathophysiology of FM. Management with antioxidants, vita-
mins, coenzyme Q10, and melatonin, in addition to the antidepressants and structural 
analogs of the gamma-aminobutyric acid, could modify the florid symptomatology that 
patients with FM have.
Keywords: fibromyalgia, oxidative stress, mitochondrial dysfunction, autophagy, 
antioxidants, antioxidant vitamins
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1. Introduction
1.1. Fibromyalgia
Fibromyalgia (FM) is a syndrome characterized by generalized pain, muscle rigidity, poor 
quality of sleep, fatigue, cognitive dysfunction, anxiety, episodes of depression, overall sen-
sitivity, and deterioration in the performance of day-to-day activities [1, 2]. The incidence of 
FM is higher in women than in men in all decades of life, and it generally appears between 
30 and 35 years of age [3, 4]. The prevalence of FM increases with age, reaching a maximum 
peak around the seventh decade. Fibromyalgia affects about 5% of the population worldwide 
[5]. According to the classification of the American College of Rheumatology, the definition of 
FM encompasses two variables: (a) bilateral pain above and below the waist with centralized 
pain and (b) chronic generalized pain for 3 months with pain on palpation in at least 11 of 18 
specific body sites (sensitive spots) [6]. In the presentation of FM alterations to the central and 
autonomous nervous system, and alterations to the neurotransmitters, hormones, the external 
immune system, psychiatric conditions, and stress factors are involved [7]. Along with pain 
there are frequent disturbances in sleep, fatigue, morning rigidity, a subjective sensation of 
the accumulation of bodily fluids, paresthesias of the extremities, depression, headache, diz-
ziness, and intestinal disturbances, which cause a decrease in quality of life [8]. The current 
review describes the oxidative stress, mitochondrial alterations, autophagy, antioxidants, and 
alternatives to the pharmacological management of FM.
1.2. Etiology
The etiology and the pathophysiological mechanisms of FM are still unknown and continue 
to be a challenging clinical entity for researchers and clinicians [9]. Some studies suggest 
that the involvement of the hypothalamus-pituitary–adrenal axis and the autonomic nervous 
system in response to stress is present in patients who are vulnerable to suffering with FM 
or its symptoms [10]. Neuroendocrine factors, anomalies of the autonomic nervous system, 
genetic characteristics, environmental changes, psychosocial changes, and oxidative stress 
are involved in the pathophysiology of FM [11]. There is a high prevalence of FM among 
relatives of patients who also suffer from it, which is attributed to the combination of envi-
ronmental and genetic factors [12]. Genetic studies suggest that the association with poly-
morphisms of the serotoninergic, dopaminergic, and catecholaminergic pathways found is 
implicated in the transmission and modulation of pain [11]. One theory of etiology suggests 
that infections are capable of activating inflammatory cytokines that could modify the central 
and peripheral perception of pain in FM. FM is characterized by chronic pain of unknown 
origin. Evidence suggests that sensitized neurons in the spinal cord of the dorsal horn are 
responsible for processing increased pain from peripheral nociceptive signals, glial activa-
tion, apparently by cytokines and excitatory amino acids that could play a role in the ini-
tiation and perpetuation of the pain due to acute or repetitive tissue injury [13]. Three FM 
subgroups have been described based on the predominant symptoms, depending on the 
following domains: psychosocial (depression/anxiety), cognitive (catastrophic/pain control), 
and neurobiology (sensitivity) [14]. The proportion of new patients with FM varies between 
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10 and 20% in clinics for patients with rheumatic diseases, while in clinics not specialized 
for rheumatic illnesses the prevalence is >2.1–5.7% [15]. Amitriptyline is the most common 
prescription drug for the management of FM. Amitriptyline has the ability to influence the 
autonomic nervous system [16].
2. Oxidative stress
Oxygen is used by the eukaryotic cells for metabolic transformations and the production of 
energy by the mitochondria. Under physiologic conditions, there is a beneficial endogenous 
production of reactive oxygen species (ROS) and reactive nitrogen species (RNS) that interact 
as signaling molecules in multiple physiological mechanisms (Figure 1). The ROS have bac-
tericide activity of the phagocytes, act in the transduction of signals, and in the regulation of 
cellular growth and the redox state of the cell, among other mechanisms [17]. When the ROS 
or RNS are produced in excess or are not eliminated by the antioxidants, the oxidative stress 
with the capacity to damage the macromolecules (carbohydrates, proteins, lipids, DNA, and 
organelles) is produced [18, 19]. In relation to FM, it is important to mention that the cells 
of the central nervous system are highly vulnerable to the toxic effects of free radicals when 
Figure 1. Formation of reactive oxygen and nitrogen species in mitochondria. The process is mediated by oxidative 
phosphorylation and the activity of the mitochondrial NO synthase: In physiological conditions, the production of ROS 
and RNS is reduced by multiple enzymatic scavengers that involved SOD, GPx, and catalase. When the mitochondria 
suffer an insult, the increase of the leakage of electrons to the matrix leads to an overload to the capacity of the enzymatic 
systems and leads to toxicity of the cell. Vectors of reactions and products. The physiological pathway for formation of 
oxidative stress. Leakage of electron to matrix. Pathophysiological pathway for formation of ROS and RNS.
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compared to other organs in the body because they have a high index of oxidative meta-
bolic activity and a low level of protector antioxidant enzymes, with an anatomical neuronal 
network that is vulnerable to interruption and high concentrations of polyunsaturated fatty 
acids of the membrane that are easily oxidized [20]. One of the primary enzyme sources of the 
superoxide anion (O2.−) is the xanthine oxidase. The purine nucleotides are degraded where 
the phosphate group is lost by the action of the 5′-nucleotidase. The adenosine is deaminated 
to inosine by the adenosine deaminase (ADA). The inosine is hydrolyzed to produce the 
purine base hypoxanthine, which is subsequently oxidized to xanthine and later to uric acid 
by the xanthine oxidase. The xanthine oxidase is an important enzyme that contains iron 
and molybdenum. The enzyme exists primarily in the form of xanthine dehydrogenase and 
can convert into xanthine oxidase through diverse conditions including proteolysis, homog-
enization, and the oxidation of sulfhydryl [21]. Oxidative stress appears to be involved in 
the severity of symptoms in FM; thus, the antioxidant therapy should be investigated as a 
possible alternative to adjunct management of FM. Blockage of the production of ROS by the 
mitochondria offers a new therapeutic strategy to diminish the symptoms of FM and other 
inflammatory states.
2.1. Lipoperoxides in fibromyalgia
The overproduction of ROS favors lipid peroxidation (LPO) that leads to the oxidative 
destruction of the polyunsaturated fatty acids, components of the cellular membranes, and 
favors the production of cytotoxic metabolites and aldehyde reactives [malondialdehyde 
(MDA) and 4-hydroxynonenal (HNE)] [22]. The MDA and HNE produced in relatively large 
quantities have an important capacity for diffusion from their site of origin and attack distant 
objects to form covalent bonds with diverse molecules [23]. Measuring MDA is one popular 
method in the search for LPO in bodily fluids or cell lysates. In one study reported in 2011, 
the authors found increased levels of LPO in mononuclear cells associated with the plasma 
levels of LPO and clinical symptoms of FM, within the pathophysiology of FM [24]. Research 
in LPO is highly important since the deleterious effects of oxidative stress could be prevented 
through control of the underlying pathology and the administration of antioxidants or free 
radical scavengers.
2.2. Nitric oxide in fibromyalgia
The production of nitric oxide (NO) occurs from the L-arginine by the nitric oxide synthase 
(NOS) (Figure 2). The NOS has four isoforms: neuronal (nNOS), inducible (iNOS), endothe-
lial (eNOS), and mitochondrial (mtNOS) [25]. The NO is implicated in physiological processes 
like: vasodilation, modulation of nociception, immune function, neurotransmission, and exci-
tation-contraction coupling [26]. The NO is considered an atypical neurotransmitter and a 
second messenger in the nervous system [27] or as a hormone [28]. The majority of the effects 
of NO are mediated through the activation of the guanylate-cyclase enzyme that produces 
cyclic guanosine-3,5-monophosphate (cGMP) [29]. The NO has pro-nociceptor properties in 
the neural crest and in the dorsal root ganglia that positively regulate as a result of cutane-
ous or visceral inflammation and by the peripheral lesions of the fibers. This effect could be 
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potentiated or inhibited by the NO donors [29]. In addition, a decrease in capillary volume 
of the blood vessels, structural disorganization of the capillary endothelium, and structural 
abnormalities of the mitochondria in histopathology studies of muscles have been reported 
in FM [30]. The structural damages can contribute to poor oxygen diffusion, less oxidative 
phosphorylation, and a decrease in the synthesis of ATP, which can increase oxidative stress 
and LPO of the membrane [31]. Abnormal microcirculation of the skin above sensitive spots 
in patients with FM has been reported with the use of the laser Doppler flowmetry technique 
[32]. The results support that local hypoxia and the possible decrease in concentrations of 
high-energy phosphate result in oxidative stress and LPO of the membrane. Therefore, abnor-
mal microcirculation can be a result of the abnormal regulation of capillary blood flow [33].
3. Mitochondrial alterations in fibromyalgia
Mitochondrial myopathies are disturbances that are characterized by morphological anoma-
lies of the mitochondria in muscles. Mitochondrial problems are found in the most common 
inherited metabolic illnesses. The patients who suffer from mitochondrial myopathies can 
Figure 2. Mechanisms involved in the presentation of fibromyalgia. The alterations involved in the presentation of 
fibromyalgia. The etiology and symptomatology of the appearance of fibromyalgia and events may be the cause or 
consequence of having FM.
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present symptomatology characterized by muscle weakness, pain, fatigue, and exercise intol-
erance that progressively worsen over time, similar to what happens in patients with FM 
[34]. Defects in any part of the cycle in the generation of ATP by the mitochondria can alter 
mitochondrial energy production and cause symptoms [35]. Oxidative stress is implicated in 
the pathogenesis of FM, which indicates that mitochondrial dysfunction can be associated 
with FM [36]. In fact, a decrease in the quantity of mitochondrial mass and the coenzyme 
Q10 (CoQ10) in the production of mitochondrial ROS in mononuclear blood cells has been 
detected in patients who suffer from FM [37]. Reports of muscle biopsies from the trape-
zius muscle have shown inflammatory markers, abnormal mitochondria, accumulation of 
sub-sarcolemma mitochondria, higher incidence of irregular red fibers, and defects of the 
cytochrome-c oxidase (Complex IV of oxidative phosphorylation) [38]. In addition, the impli-
cation of mitochondrial oxidative stress in peripheral nociception described as a predominant 
symptom mediated by the inflammatory state in FM has been previously reported [39].
4. Autophagy
Autophagy is the process of cellular recycling that promotes energy efficiency through the 
generation of ATP and mediates damage control through the elimination of organelles and 
nonfunctional proteins, in regulating the degradation of cytosolic components by the lipo-
somes [40]. Autophagy is the main catabolic pathway through which macromolecules and 
organelles of the eukaryotic cells are degraded and recycled. This pathway is activated under 
conditions of environmental stress and during the development of diverse pathologic situ-
ations. Autophagy plays an essential role in the cellular differentiation, development, and 
response to stress. It is activated during amino acid deprivation and is associated with neuro-
degenerative illnesses, cancer, pathogenic infections, and myopathies [41]. Autophagy can be 
induced by diverse causes: mitochondrial dysfunctions, infections of intracellular pathogens, 
and intrinsic cellular signals. Folded or damaged proteins, the organelles, and the intracel-
lular pathogens are isolated by double membrane vesicles forming autophagosomes, which, 
on fusing with the lysosomes, convert into autolysosomes to be degraded [42]. Autophagy is 
an active process that plays the role of cleansing in maintaining the integrity of the intracel-
lular organelles and proteins; however, autophagy is strongly induced by starvation, as in 
the case of cellular hypoxia, and is a key component in the adaptive response of the cells and 
organisms to the lack of nutrients, in order to promote cellular survival until the nutrients are 
made available once more [43]. Thirty-two different genes have been identified in relation 
to autophagy, obtained by genetic screening in yeasts. Many of these genes can be found in 
mold, plants, worms, flies, and in mammals, emphasizing, through phylogeny, the impor-
tance of the autophagy process in response to starvation [44]. Three types of autophagy that 
promote proteolytic degradation of the cytosolic components in lysosomes have been defined:
a. Macroautophagy: the cytoplasmic load is given to the lysosomes through a vesicle with a 
double-layered membrane called an autophagosome, which fuses with the lysosome to 
form the autolysosome. Macroautophagy is capable of engulfing large structures through 
selective and nonselective mechanisms.
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b. Microautophagy: the cytosolic components are absorbed directly by the lysosome through 
engulfment by the lysosomal membrane. In microautophagy, large structures can also be 
ingested through selective and nonselective mechanisms.
c. Chaperone-mediated autophagy: targeted proteins are translocated through the lysosomal 
membrane forming a complex with protein chaperones (i.e., Hsc-70) that are recognized 
by the membrane protein 2A associated with the lysosomes of the lysosomal membrane, 
causing unfolding and degradation [45].
The autophagy mechanism begins with an isolation membrane (phagophore), probably 
derived from the lipid bilayer originating in the endoplasmic reticulum (ER), and/or through 
the Golgi apparatus and endosomes [46]. The phagophore expands to engulf intracellu-
lar components, isolating protein aggregates, organelles and ribosomes, and forming an 
autophagosome with a double membrane. The autophagosome matures through fusion with 
the lysosome, promoting the degradation of the autophagosome content by acidic lysosome 
proteases. The lysosomal permeases and transporters export amino acids and by-products 
of degradation to the cytoplasm, where they can be reused for the construction of macro-
molecules and for metabolism [47]. Selective degradation of the mitochondria mediated by 
autophagy is called mitophagy [48]. It seems the absence of functional mitochondria pro-
duced by metabolic deregulation and autophagy obligates the muscle cells to gain energy 
without the participation of the Krebs cycle, in comparison to intact mitochondria. The mito-
chondrial degradation dependent on autophagy or mitophagy is an important process to 
maintain the critical integrity of the mitochondria and to limit the production of ROS [49]. The 
deregulation of autophagy and mitochondrial dysfunction could represent key aspects in the 
pathophysiology of FM [50]. The authors demonstrate that CoQ deficient fibroblasts exhibite 
increased levels of lysosomal markers (beta-galactosidase, cathepsin, LC3, and Lyso Tracker), 
and enhanced expression of autophagic genes at both transcriptional and translational levels, 
indicating the presence of autophagy [51]. CoQ10 deficiency apparently induces autophagy 
activation in mononuclear blood cells (BMCs) of FM patients by finding increased levels of 
acid vacuoles in BMCs identified by Lysotracker fluorescence and flow cytometry analysis. 
The authors suggest restoring mitochondrial functionality with CoQ10 supplementation as 
demonstrated in in vitro studies with decreased lysosomal activity following treatment with 
CoQ10 [52]. Autophagy is an attractive, strategic target for investigation of bodily fluids or 
muscle biopsies in patients who suffer FM (Figure 2).
5. Managing fibromyalgia
Treatment for FM is a challenge and often requires nonpharmacological and pharmacologi-
cal treatment [53]. The dietary habits of FM patients are important, and diverse studies have 
demonstrated improvement of symptoms with the ingestion of healthy, balanced diets [54]. 
However, the heterogeneity of symptoms that presents in FM deserves individualized treat-
ment. Therapy should include physiotherapy, psychotherapy, pharmacotherapy, and edu-
cate the patient on the pathology of FM [55].
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5.1. Amitriptyline in fibromyalgia
Amitriptyline is a tricyclic antidepressant known to inhibit the reuptake of serotonin and 
norepinephrine, and it has been used for a long period of time in the management of neuro-
pathic pain and FM [56]. Amitriptyline is the pharmacological treatment with the most solid 
evidence in FM management, although exhaustive follow-up for secondary effects is recom-
mended [57]. The administration of the medication is recommended for short periods to con-
trol pain. It was previously reported that the administration of 50 mg/day of amitriptyline at 
bedtime, for 9 weeks, in patients with FM, significantly improved pain, muscle rigidity, and 
sleep, compared to patients treated with placebo [58]. In another study, 62 patients with FM 
received 25 mg/day of amitriptyline at bedtime with an additional 500 mg of naproxen x2 
daily, or a placebo for 6 weeks. Those who received amitriptyline had significant improve-
ments in pain, sleep disturbances, and fatigue on waking, compared to those who received 
placebo. The authors did not find significant differences in improvement of pain among 
patients who only received amitriptyline or amitriptyline with naproxen [59]. The guidelines 
of the European League Against Rheumatism (EULAR) suggest that the management of FM 
with low doses of amitriptyline of 25 mg/day improves pain, sleep, and fatigue at 6–8 weeks 
without finding evidence that the use of 50 mg/day was superior [60]. However, the toxic-
ity induced by amitriptyline implies the early activation of the mitofagia that subsequently 
changes to apoptosis. Amitriptyline induces mitochondrial dysfunction and oxidative stress 
in HepG2 cells. Amitriptyline specifically inhibits mitochondrial complex III activity that is 
associated with decreased mitochondrial membrane potential (ΔΨm) and increased ROS 
production. Transmission electron microscopy studies revealed structurally abnormal mito-
chondria that were engulfed by double membrane structures resembling autophagosomes. 
Pharmacological or genetic inhibition of autophagy exacerbated the deleterious effects 
of amitriptyline on hepatoma cells and leads to increased apoptosis. These results suggest 
that mitophagy acts as a mechanism of initial adaptation of cell survival. However, persis-
tent mitochondrial damage induces extensive and lethal mitophagy, autophagic stress, and 
autophagic permeabilization leading to cell death by apoptosis [61].
5.2. Pregabalin
The postsynaptic NMDA receptors can alter the presynaptic transport of the vesicles that con-
tain neurotransmitters through the NO pathway that diffuses to the presynaptic membrane 
and alters traffic of the vesicles [67].
5.3. Co-enzyme Q10 (CoQ10)
The CoQ10, a small lipophilic molecule located in the internal mitochondrial membrane, 
transfers reducing equivalents of the complexes I and II to the complex III of the mitochon-
drial respiratory chain. The CoQ10 is crucial for the efficiency of the mitochondrial chain, and 
there is existing evidence that reports CoQ10 as affecting the expression of genes involved in 
the inflammatory pathways [62]. The presence of mitochondrial dysfunction has been pro-
posed as a relevant fact in the pathogenesis of FM [63]. The mitochondria generate energy 
primarily in the form of an electrochemical proton gradient that fuels the production of ATP, 
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ion  transport, and metabolism. The mitochondria are the primary sources of ROS in the com-
plexes I and III, together with CoQ10 [64]. Management with CoQ10 could be useful as an 
alternative treatment in FM; however, more studies are needed to confirm whether the ben-
eficial effect is real. More detailed studies through analysis in double blind placebo-controlled 
clinical trials are required on the effect of CoQ10 in bodily fluids and/or muscle biopsies [65]. 
In a study by Alcocer-Gomez E et al. included four patients with FM who measured the visual 
analogue scale (pain, fatigue and sleep), the Generalized Pain Index, the symptom severity 
scale and the Scl-90-R using the FM Impact Questionnaire High-performance liquid chroma-
tography the CoQ10 content of patients with FM, and the authors found that CoQ10 in the 
four patients had defiecincy before the treatment, and after the treatment with CoQ10 patients 
showed significant improvement in clinical symptoms [66].
6. Antioxidants
Antioxidants, like the superoxide dismutase (SOD), catalase, and the glutathione peroxi-
dase (GPx), are enzymes of the defense system that work to prevent oxidative stress through 
inactivation of the ROS. The SOD enzyme eliminates the damaging effects of the free radi-
cals through the conversion of the radical O2.− into hydrogen peroxide (H
2
O
2
), and the GPx 
converts H
2
O
2
 into oxygen and water [67]. The principle intracellular antioxidant enzymes, 
copper, zinc-SOD (Cu-Zn-SOD) in the cytoplasm, and the manganese-SOD (MnSOD) in the 
mitochondria, specifically reduce the O2.− radicals to H
2
O
2
. Normally, there is an equilibrium 
between the ROS and the antioxidants in the cell, in the membranes, and in the extracellular 
space. However, the antioxidants are overwhelmed by the excessive production of ROS. The 
ROS attack the polyunsaturated fatty acids of the membrane producing LPO, resulting in 
alteration to the membrane permeability and changes to the membrane potential. The mea-
surement of thiobarbituric acid reactive substances (TBARS), MDA, or 4-hydroxynonenal is 
the most common method applied to measure LPO [68]. The central nervous system is espe-
cially sensitive to ROS due to its high content of lipids compared to other areas of the body 
(Figure 1) [34].
6.1. Melatonin
Pain is a dynamic phenomenon resultant of the activity of the endogenous system of excita-
tion and inhibition of pain. The efficiency of the system in FM has been related to the quality 
of sleep [69]. The relationship between pain and quality of sleep is supported on a neurobio-
logical basis by the neurotransmitters involved: norepinephrine, serotonin, and dopamine 
[70]. The effect of melatonin on pain has been demonstrated in studies on inflammatory pain 
in experimental animals with neuropathic pain [71, 72] and in acute and chronic pain in clini-
cal studies [73, 74]. Since the most frequent complaints in patients with FM are sleep altera-
tions, fatigue, and chronic pain, these symptoms could be a consequence of the disruption 
of melatonin secretion [75]. Additionally, there is information that the serum levels of the 
precursors to melatonin (tryptophan and serotonin) are diminished in patients with FM [76]. 
The deficiency of melatonin in FM could explain the lack of reparative sleep and could be a 
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mechanism involved in the regulation of dysfunctional pain [77]. There have been reports 
of studies which suggest that melatonin increases the effect of the descending pain inhibi-
tory system, which involves anatomical connections between cortical regions and the brain-
stem in the human brain [78]. Therefore, the restoration of melatonin could be an additional 
mechanism to explain the discrepancy of its effect compared to amitriptyline. In a phase II 
randomized controlled clinical trial, it was demonstrated that the exogenous administration 
of 10 mg every 24 h of melatonin augmented the endogenous inhibitory system of pain regu-
lation, evaluated by a numerical scale (0–10), and demonstrated that the association between 
melatonin with amitriptyline gave better results than the amitriptyline alone, as determined 
by the visual analog pain scale [79]. Another randomized trial demonstrated that the admin-
istration of melatonin alone or in combination with fluoxetine (3–5 mg/day) was efficient in 
treating FM [80]. However, clear and conclusive evidence from clinical trials or prospective 
cohorts with prolonged follow-up on the effect of melatonin in patients suffering from FM is 
still lacking. Melatonin behaves as a free radical scavenger and therefore as a potent antioxi-
dant. Melatonin has physical–chemical advantages over other antioxidant molecules. It is a 
hormone that is found naturally in the body. Melatonin molecules enter all subcellular organs 
and compartments. Melatonin detoxifies up to 10 Free Radicals [81]. Compared with other 
antioxidants, melatonin has equal or better efficacy in the protection of tissues from oxida-
tive lesions such as vitamin C and E. Another inherent feature of melatonin is mitochondrial 
membrane selectivity and may be the most interesting advantage of pineal hormone [82]. 
Even melatonin is an effective antioxidant in the prevention of hepatotoxicity induced by 
amitriptyline [83].
7. Vitamins
Vegetarian diets seem to alleviate some symptoms of FM due to a low content of fat and pro-
teins, high levels of fiber, vitamin C, beta-carotenes, minerals (magnesium, potassium, zinc, 
and selenium), and antioxidants [49].
In the first controlled pilot study to establish the safety and feasibility of intravenous treat-
ment of micronutrients based on water-soluble vitamins and minerals in FM (Myer’s cock-
tail), the authors reported that the majority of subjects experienced alleviation compared to 
baseline symptomatology, but they did not observe significant differences between the ther-
apy and the placebo, considering the relationship uncertain between the placebo and micro-
nutrients in FM [84]. According to the Brazilian Society of Rheumatology, the ingestion of 
sugar, salt, fat, and alcohol should be reduced, and the ingestion of fiber, fruits, vegetables, 
and fluids increased, in order to avoid the appearance of chronic degenerative illnesses and 
obesity [85]. Specific micronutrients like calcium (Ca) and magnesium (Mg) are important for 
proper muscular contraction, and the increase in tryptophan intake can be beneficial in the 
synthesis of serotonin [86]. The combination of vitamins and minerals can reduce the doses 
of analgesics and improve the sensation of pain in patients with FM [87]. In the majority of 
subjects with FM, an inadequate intake of vitamin C is observed. In 2003, Richard et al. dem-
onstrated that the prolonged use of analgesics can augment the excretion of potassium and 
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vitamin C  causing anemia from iron deficiency [88]. In the study by Sakarya et al., the authors 
evaluated blood levels of antioxidant vitamins and Mg in FM patients, and they correlated 
them with clinical parameters without finding a correlation between the levels of vitamins A, 
C, E, and Mg with pain severity, functional capacity, and depression. The authors suggest that 
based on the results, the poor intake of these nutrients does not necessarily signify low blood 
levels [89]. Folate and vitamin B12 are essential for the regulation of the central nervous sys-
tem, and their deficiency can result in peripheral neuropathic pain. Vitamin C deficiency can 
cause myalgia and bone pain, and a deficiency of vitamin D can cause muscle-skeletal pain 
[90]. The fatigue present in FM seems to have similarities to the manifestations of mild thia-
mine deficiency [91]. Various similarities have been reported between FM and thiamine defi-
ciency, which include irritability, frequent headache, fatigue, muscular weakness, irritable 
bowel syndrome, and sleep disturbances. Studies have been published where anomalies in 
thiamine metabolism have been demonstrated in FM, and investigating thiamine deficiency 
together with the consumption of alcohol has been suggested in FM patients [92]. The admin-
istration of large quantities of oral thiamine increases the blood concentration to levels where 
the passive transport restores the normal glucose metabolism, and then the normal glucose 
metabolism of all the organs returns to normal values and symptoms are reduced. It is recom-
mended to prescribe the permanent use of high doses of thiamine in FM [93]. Vitamins A, E, 
and C are potent nonenzymatic antioxidants [94]. Vitamins A and E are essential fat-soluble 
vitamins, are the primary chain antioxidants in body tissues, are considered the first line of 
defense against LPO, they protect the cell membranes early on when the activity of free radi-
cals increases [95]. Vitamin C is the main water-soluble vitamin and is a free radical purifier 
that transforms vitamin E to its active form [96]. Magnesium (Mg) is a mineral that plays an 
important role in ATP synthesis and functions in adequate muscle metabolism [97]. Serum 
levels of Mg have been investigated in FM to reveal etiopathology [98]. Vitamin C is capable 
of accelerating the degradation of intra- and extracellular proteins targeting lysosomal lumen 
by autophagic and heterophagic pathways. Vitamin C decreased and stabilized the intra-lyso-
somal acid pH at values that resulted in maximal activation of the lysosomal hydrolases [99].
7.1. Vitamin D
Vitamin D is a hormone essential for maintaining homeostasis of the muscle-skeletal system. 
Vitamin D deficiency has been proposed as a factor associated with generalized chronic pain. 
The majority of vitamin D is produced naturally in the skin after exposure to ultraviolet B 
light (UVB) producing 25-hydroxyvitamin D (25-OHD). Vitamin D undergoes hydroxylation 
of the active form 1,25-dihydroxyvitamin D (1,25-OHD) in the liver and kidneys. Age, lati-
tude, time of day, season, skin pigmentation, adiposity, smoking, and amount of exposure to 
sunlight directly affect the production of vitamin D in the skin [100]. People who are at risk of 
vitamin D deficiency include people with dark skin, obesity, the elderly, those with chronic 
degenerative illnesses, or those with disabilities who have little exposure to sunlight [101]. 
The active form of vitamin D, 1,25-OHD, acts in the cell nucleus (genomic effects caused by 
gene over-regulation) and the cell membranes (nongenomic effects that cause rapid response) 
in more than 30 tissues and organs [102]. The muscles are a target organ for the metabolites 
of vitamin D because they contain receptors for vitamin D identified in the muscle tissues in 
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humans and animals on producing genomic effects that alter calcium, phosphate, and the 
metabolism of phospholipids [103]. These changes are important for the normal, functional 
development of the skeletal musculature. There is evidence that the ingestion of vitamin D 
improves muscle strength and functional capacity. It should be considered that vitamin D 
decreases in elderly populations, and supplementation is necessary [104]. Recent studies have 
centered on the potential therapeutic implications of vitamin D and its deficiency, in the regu-
lation of chronic pain processing in FM, through the interactions of central and peripheral 
complexes. The primary functional scenario of the interaction is based on the presence of the 
vitamin D receptor and the 1α-hydroxylase (enzyme that converts the 25-hydroxyvitamin 
D by hydroxylation to the active 1,25 di-hydroxyl-vitamin D (1,25 (OH) 2D3) in many areas 
of the human central nervous system, among which are: the prefrontal cortex, the amyg-
dala, the raphe, the gelatinous substance, the cerebellum, the hippocampus, the cingulate 
cortex, the substance nigra, the thalamus, and the hypothalamus [105]. Both the receptor and 
the enzyme have been found in neuronal and glial cells [106]. The general characteristics of 
hypovitaminosis D are body pain, especially in the shoulder, the thoracic cavity, and lumbar 
and pelvic regions. The biological relationship between generalized chronic pain and vitamin 
D deficiency continues to be an interesting investigative topic. Patients with FM could have 
vitamin D deficiencies due to the characteristics of their pain, poor mobility, or the associated 
depression that decreases free time exposed to sunlight, or by the increase in adiposity that 
favors the decrease in vitamin D synthesis. Therefore, the participation of the 1,25-OHD in 
the regulation of the immune system could be involved in vitamin D deficiency and mus-
cular pain [107]. A systematic review that sought evidence of an association between FM 
and vitamin D deficiency was inconclusive, without finding improvement in muscular pain 
after supplementation. However, patients with concurrent risk factors between FM and other 
pathologies like osteoporosis should be tested in case a vitamin D deficiency is found that 
would favor muscle strength [108]. The search between vitamin D deficiency and the pres-
ence of FM remains an inconclusive matter.
8. Conclusion
In conclusion, oxidative stress, mitochondrial dysfunction, autophagy, multivitamin deficien-
cies, and the imbalance between oxidants and antioxidants are an intriguing and clinically 
attractive topic to elucidate the state and progression of FM. Pharmacological treatment alone 
is insufficient for the majority of patients who suffer from FM syndrome. It is recommended 
to approach treatment in a multidisciplinary way in clinical practice. Moderate physical activ-
ity and the supplementation/ingestion of antioxidants could be beneficial in regulating the 
oxidative state.
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